Impact of HIV infection on survival among women with stage I-III breast cancer: Results from the South African breast cancer and HIV outcomes study.
HIV
South Africa
breast cancer
overall survival
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 07 2022
15 07 2022
Historique:
revised:
01
02
2022
received:
01
10
2021
accepted:
08
02
2022
pubmed:
27
2
2022
medline:
27
5
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
In some countries of sub-Saharan Africa, the prevalence of HIV exceeds 20%; in South Africa, 20.4% of people are living with HIV. We examined the impact of HIV infection on the overall survival (OS) of women with nonmetastatic breast cancer (BC) enrolled in the South African Breast Cancer and HIV Outcomes (SABCHO) study. We recruited women with newly diagnosed BC at six public hospitals from 1 July 2015 to 30 June 2019. Among women with stages I-III BC, we compared those with and without HIV infection on sociodemographic, clinical, and treatment factors. We analyzed the impact of HIV on OS using multivariable Cox proportional hazard models. Of 2367 women with stages I-III BC, 499 (21.1%) had HIV and 1868 (78.9%) did not. With a median follow-up of 29 months, 2-year OS was poorer among women living with HIV (WLWH) than among HIV-uninfected women (72.4% vs 80.1%, P < .001; adjusted hazard ratio (aHR) 1.49, 95% confidence interval (CI) = 1.22-1.83). This finding was consistent across age groups ≥45 years and <45 years, stage I-II BC and stage III BC, and ER/PR status (all P < .03). Both WLWH with <50 viral load copies/mL and WLWH with ≥50 viral load copies/mL had poorer survival than HIV-uninfected BC patients [aHR: 1.35 (1.09-1.66) and 1.54 (1.20-2.00), respectively], as did WLWH who had ≥200 CD4+ cells/mL at diagnosis [aHR: 1.39 (1.15-1.67)]. Because receipt of antiretroviral therapy has become widespread, WLWH is surviving long enough to develop BC; more research is needed on the causes of their poor survival.
Identifiants
pubmed: 35218568
doi: 10.1002/ijc.33981
pmc: PMC9133061
mid: NIHMS1783761
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
209-221Subventions
Organisme : NCI NIH HHS
ID : R01 CA192627
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA250012
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA094061
Pays : United States
Organisme : National Institute of Health/National Cancer Institute
ID : R01-CA250012
Informations de copyright
© 2022 UICC.
Références
J Am Coll Surg. 2009 Mar;208(3):341-7
pubmed: 19317994
Breast Cancer Res Treat. 2012 Feb;131(3):1061-6
pubmed: 22080245
PLoS One. 2009 Nov 11;4(11):e7695
pubmed: 19907646
Lancet Glob Health. 2020 Sep;8(9):e1203-e1212
pubmed: 32827482
AIDS. 2021 Mar 15;35(4):605-618
pubmed: 33394680
J Glob Oncol. 2017 Apr;3(2):114-124
pubmed: 28706996
Mol Cell Endocrinol. 2014 Jan 25;382(1):673-682
pubmed: 23791814
Oncologist. 2019 Jul;24(7):933-944
pubmed: 30518615
J Clin Oncol. 2016 Jul 20;34(21):2452-9
pubmed: 27217455
J Biosoc Sci. 2012 Jul;44(4):459-80
pubmed: 22273351
Int J Cancer. 2018 Apr 15;142(8):1568-1579
pubmed: 29197068
Breast. 2019 Feb;43:123-129
pubmed: 30550925
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
PLoS One. 2017 Feb 13;12(2):e0171024
pubmed: 28192444
Breast Cancer Res Treat. 2020 Dec;184(3):861-872
pubmed: 32875480
Int J Cancer. 2019 Mar 15;144(6):1251-1261
pubmed: 30367449
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
Lancet Oncol. 2008 Aug;9(8):730-56
pubmed: 18639491
Breast. 2015 Dec;24(6):713-7
pubmed: 26371692
J Clin Oncol. 2015 Jul 20;33(21):2376-83
pubmed: 26077242
Cancer. 2019 Aug 15;125(16):2868-2876
pubmed: 31050361
S Afr J Surg. 2016 Jun;54(2):10-13
pubmed: 28240498
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1027-1033
pubmed: 28619832
BMJ Glob Health. 2016 Dec 30;1(4):e000125
pubmed: 28588979
Sci Rep. 2018 Feb 16;8(1):3133
pubmed: 29453393
Medicine (Baltimore). 2020 Jan;99(3):e18745
pubmed: 32011455
World J Surg Oncol. 2015 Jul 19;13:220
pubmed: 26187151
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241185
N Engl J Med. 2014 Oct 2;371(14):1344-53
pubmed: 25265493
Breast Cancer Res Treat. 2018 May;169(1):175-187
pubmed: 29368311
Breast Cancer Res Treat. 2021 Aug;189(1):285-296
pubmed: 34125339
Viruses. 2019 Feb 27;11(3):
pubmed: 30818749
J Glob Oncol. 2019 Nov;5:1-16
pubmed: 31770052
J Coll Physicians Surg Pak. 2021 Feb;31(2):166-170
pubmed: 33645183
Science. 2013 Feb 22;339(6122):961-5
pubmed: 23430655
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
J Clin Oncol. 2008 Jul 10;26(20):3324-30
pubmed: 18612148
PLoS One. 2018 Feb 2;13(2):e0192071
pubmed: 29394271
Am J Public Health. 2014 Jul;104(7):e77-84
pubmed: 24832420
ESMO Open. 2018 Feb 2;3(2):e000285
pubmed: 29464109
Breast Cancer Res Treat. 2021 Jan;185(1):117-124
pubmed: 32948993
Cytokine Growth Factor Rev. 2006 Oct;17(5):325-37
pubmed: 16931107
Int J Cancer. 2014 Nov 1;135(9):2173-82
pubmed: 24658866
JAMA Oncol. 2015 Jul;1(4):448-54
pubmed: 26181252
Cancer Med. 2019 Nov;8(15):6662-6670
pubmed: 31549794
Ann Epidemiol. 2017 Oct;27(10):659-671.e7
pubmed: 29128086
Int J Cancer. 2020 Jul 15;147(2):361-374
pubmed: 31600408
JAMA Oncol. 2019 Sep 01;5(9):e191742
pubmed: 31369037
PLoS Med. 2013;10(4):e1001418
pubmed: 23585736